Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Incremental Prognostic Utility of CBC-derived Inflammatory Indices After Incomplete Coronary Revascularization: Association With 12-months Cardiovascular Outcomes (CBCRSS2026)

maanantai 2. marraskuuta 2026 päivittänyt: Ahmed Amr Ahmed Aly, Assiut University

Coronary artery disease (CAD) remains the top cause of death worldwide . While guideline-directed medical therapy forms the foundation of CAD treatment , revascularization via percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery is critical for complex cases, such as multivessel disease or acute coronary syndromes (ACS). Post-procedure, patients are classified as having achieved complete revascularization (CR) or incomplete revascularization (ICR). The residual SYNTAX score (rSS) objectively quantifies this leftover stenosis, where higher scores predict worse long-term outcomes .

Concurrently, inflammation heavily drives ACS pathogenesis, plaque instability, and residual cardiovascular risk . Complete blood count (CBC)-derived inflammatory indices - specifically NLR, PLR, SII, and MLR - offer inexpensive, accessible markers of this systemic inflammatory status .

The Knowledge Gap: Most research evaluates rSS alongside traditional risk factors, ignoring systemic inflammation in a unified prognostic framework. Existing studies on these CBC indices often focus broadly on STEMI or general PCI populations, rather than isolated ICR patients. Furthermore, they rely on single measurements, failing to evaluate the incremental value or dynamic changes (baseline vs. post-procedural) of these indices over rSS alone.

Study Hypotheses: This study hypothesizes that baseline, 24-hour post-PCI, and dynamic changes in NLR, PLR, SII, and MLR are independently associated with major adverse cardiovascular events (MACE) in angiographically documented ICR patients. Ultimately, adding these inflammatory indices to the rSS will significantly improve MACE prognostic discrimination, yielding superior AUC, NRI, and IDI values compared to using rSS alone.

Primary aim: To determine whether the addition of baseline and post-PCI CBC-derived inflammatory indices (NLR and SII) to rSS improves discrimination for MACE compared with rSS alone.

Secondary aims:

  1. To determine whether the addition of baseline and post-PCI PLR and MLR to rSS improves discrimination for MACE compared with rSS alone.
  2. To assess the correlation between baseline and post-PCI NLR, PLR, SII, MLR and rSS as a continuous variable.
  3. To determine whether inflammatory indices are independently associated with MACE after adjustment for demographic, clinical, laboratory, angiographic, and procedural variables.
  4. To assess whether changes in NLR, PLR, SII, and MLR from baseline to 24 h post-PCI provide incremental prognostic information beyond static values and rSS.

Patients .

  • Patients presenting with STEMI or high risk NSTEMI undergoing Primary PCI and with incomplete revascularization will be included in the study.
  • Eligible patients will be subjected to the following:

I- History taking and examination 2-After completion of the index PCI, Incomplete revascularization will be defined as the presence of significant residual coronary artery disease, resulting in a rSS >0 . .

3-A baseline CBC will be obtained immediately after admission, before coronary angiography/PCI . second CBC will be obtained (24±2 hours) after PCI, the interval between PCI and 2nd CBC sampling will be recorded The following indices will be calculated: NLR = absolute Neutrophil count\ Absolute Lymphocyte count, PLR = Platelet count\Absolute Lymphocyte count, SII = Platelets count x neutrophils count \ lymphocytes count and MLR = Monocytes count \lymphocytes count.

4-Peak troponin or CK-MB will be recorded after 12-24 hours of onset of symptoms and used as a surrogate measure of infarct size and included as a covariate in the multivariable analysis.

5-Transthoracic echocardiography will be performed by cardiologists blinded to the study within the first 24hr after PCI according to current practice guidelines 5-Patients will be followed for 12 months after the index PCI. 6-The primary endpoint will be the occurrence of major adverse cardiovascular events (MACE) during follow-up in the form of Cardiovascular death due to new ischemic event, Non-fatal myocardial infarction and Unplanned ischemia-driven repeat coronary revascularization.

Secondary end point: Onset of new ischemic events (UA, worsening of chest pain or ischemic induced heart failure)

Tutkimuksen yleiskatsaus

Tila

Ei vielä rekrytointia

Yksityiskohtainen kuvaus

. Introduction Coronary artery disease (CAD) is the leading cause of morbidity and mortality worldwide. Guideline-directed medical therapy is the foundation of treatment for all patients with CAD and can stabilize or regress coronary artery atherosclerotic plaques, preventing coronary thrombosis, acute myocardial infarction (MI) and cardiac death. Revascularization with either percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery in selected patients with extensive CAD, including those with left ventricular dysfunction, left main CAD or multivessel disease (MVD), and acute coronary syndromes (ACS) can further reduce angina, improve functional capacity and quality of life, and increase infarct-free survival. Depending on whether residual CAD is present after treatment, PCI and CABG surgery can be described as having achieved complete revascularization (CR) or incomplete revascularization (ICR), the extent of which might have important prognostic implications.

The residual SYNTAX score (rSS), initially developed to quantify the extent and complexity of residual coronary stenosis, is calculated by reapplying the SYNTAX scoring system to post-PCI coronary angiograms. This score serves as an objective measure of the angiographic completeness of revascularization. Previous studies have demonstrated that a higher rSS is predictive of worse long-term outcomes after PCI.

Over the years, researchers have elucidated the multifaceted roles played by systemic and localized inflammatory processes in ACS, encompassing aspects such as endothelial dysfunction, immune response modulation, plaque stability, and thrombus formation. Inflammation can destabilize atherosclerotic plaques, inducing acute coronary events. Furthermore, inflammation is increasingly recognized as a contributor to the pathogenesis of ACS and an important determinant of prognosis and therapeutic response in affected patients. Understanding the inflammatory status in CAD can potentially lead to the development of more effective prognostic strategies.

Despite significant advances in reperfusion strategies, pharmacologic therapy, and the management of modifiable risk factors such as diabetes, dyslipidemia, and hypertension, adverse cardiovascular events continue to occur after acute myocardial infarction. The determinants of this residual risk (ie, the risk that persists despite optimal control of known modifiable factors) remain uncertain. Among these determinants, inflammation plays a complex but increasingly recognized role. Recent studies suggest that residual inflammatory risk is a stronger predictor of recurrent events and mortality.

It is known that coronary artery disease is characterized by a high inflammatory burden, and several studies demonstrated that hematological parameters are associated with the severity and prognosis of coronary artery disease . Complete blood count (CBC)-derived inflammatory indices provide inexpensive and readily available markers of systemic inflammatory status.

Four increasingly studied indices are : Neutrophil-to-lymphocyte ratio (NLR), Platelet-to-lymphocyte ratio (PLR), Systemic immune-inflammation index (SII) and Monocyte-to-lymphocyte ratio (MLR).

Gap in knowledge Despite extensive evidence that the rSS quantifies the burden of untreated coronary disease and predicts adverse outcomes after PCI, most studies have evaluated rSS alone or in combination with traditional clinical risk factors, without integrating inexpensive CBC-derived inflammatory indices into a unified prognostic framework for patients with incomplete revascularization. Recent work has shown that systemic immune-inflammatory indices such as the NLR, PLR, SII, and MLR are associated with rSS and with poorer outcomes in ACS, but these investigations have largely focused on ST elevation myocardial infarction (STEMI) or general PCI patients and have rarely focused on isolated patients with angiographically confirmed residual coronary disease. Furthermore, prior studies have typically relied on single measurements of inflammatory indices and have not systematically examined the incremental discriminative value of baseline and post-procedural inflammatory indices - nor their dynamic changes- over rSS In addition, the relationship between these CBC-derived indices, rSS, and MACE in the specific context of incomplete revascularization.

Study hypotheses Based on these considerations, The investigators hypothesize that CBC-derived inflammatory indices (NLR, PLR, SII, and MLR) measured at baseline and 24 hours after PCI, as well as their changes post PCI, are independently associated with the occurrence of MACE in patients with angiographically documented incomplete coronary revascularization, after adjustment for established clinical, laboratory, and angiographic risk factors. The investigators further hypothesize that adding these inflammatory indices to rSS significantly improves prognostic discrimination for MACE compared with rSS alone, as reflected by higher area under the ROC curve (AUC) and favorable NRI and IDI values.

2. Aim of the work Primary Aim To determine whether the addition of baseline and post-PCI CBC-derived inflammatory indices (NLR and SII) to rSS improves discrimination for MACE compared with rSS alone.

Secondary Aims

  1. To determine whether the addition of baseline and post-PCI PLR and MLR to rSS improves discrimination for MACE compared with rSS alone.
  2. To assess the correlation between baseline and post-PCI NLR, PLR, SII, MLR and rSS as a continuous variable.
  3. To determine whether inflammatory indices are independently associated with MACE after adjustment for demographic, clinical, laboratory, angiographic, and procedural variables.
  4. To assess whether changes in NLR, PLR, SII, and MLR from baseline to 24 h post-PCI provide incremental prognostic information beyond static values and rSS.

Patient and Methods The study will be conducted at the Assiut University Heart Hospital 300 STEMI patients and 140 high risk NSTEMI patients undergoing primary PCI, who have residual untreated coronary disease after the index PCI, will be consecutively enrolled and followed prospectively for clinical outcomes.

All patients will be subjected to the following:

I- History taking and examination: to assess cardiovascular risk factors blood pressure, heart rate and cardiac examination. The time of symptom onset (or last-known-well time) will be documented for all patients.

II- Clinical presentation classification:

Patients will be classified as STEMI (group A) and high risk NSTEMI (group B) according to current ESC/ACC diagnostic criteria at presentation. This classification will be recorded as a pre-specified covariate for all subsequent analyses.

III- Residual SYNTAX Score (rSS) calculation:

After completion of the index PCI, Incomplete revascularization will be defined as the presence of significant residual coronary artery disease, resulting in a rSS >0 31. Any subsequent staged PCI performed for the residual disease during the 12-month follow-up period will be recorded, together with its date; staged-PCI status will be modeled as a time-varying covariate in the survival analysis (see Statistical Analysis) rather than as a fixed baseline characteristic, in order to avoid immortal time bias. The index rSS, measured immediately after the index procedure, will remain the fixed exposure variable of interest throughout follow-up.

rSS will be calculated by a cardiologist blinded to outcomes and CBC indices results.

rSS will be calculated by summing up the individual scores for each residual lesion with diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained after the procedure 31.

rSS will be calculated using both the original SYNTAX Score Calculator, currently found on http:// syntaxscore. org, and the web version of the updated SYNTAX Score 2020 Calculator, which is found on http:// synta xscor e2020. com.

IV- CBC-Derived Inflammatory Indices A baseline CBC will be obtained immediately after admission, before coronary angiography/PCI and before administration of treatments likely to significantly modify the inflammatory response. The interval between documented symptom onset and baseline CBC sampling (symptom-to-draw interval, in hours) will be recorded and used as a covariate in the multivariable analysis.

A second CBC will be obtained (24±2 hours) after PCI, the interval between PCI and 2nd CBC sampling will be recorded (balloon-to-draw interval, in hours).

  • The following will be recorded:

    • Total leukocyte count
    • Absolute neutrophil count
    • Absolute lymphocyte count
    • Absolute monocyte count
    • Platelet count
  • The following indices will be calculated:

NLR = absolute Neutrophil count\ Absolute Lymphocyte count PLR = Platelet count\Absolute Lymphocyte count SII = Platelets count x neutrophils count \ lymphocytes count MLR = Monocytes count \lymphocytes count

V- Biomarkers of myocardial injury:

Peak troponin or CK-MB will be recorded after 12-24 hours of onset of symptoms and used as a surrogate measure of infarct size and included as a covariate in the multivariable analysis.

VI- Echocardiography:

Transthoracic echocardiography will be performed by cardiologists blinded to the study within the first 24hr after PCI according to current practice guidelines, using a commercially available device (GE Vivid S6 ultrasound device). The left ventricular ejection fraction (EF) will be obtained by the modified Simpson's rule.

VII- Medications:

Any medications that may affect inflammatory indices (Antiplatelets, statins, corticosteroids, ACE-I, ARBs, B-blockers or SGLT2-I) will be recorded

VIII- Follow-Up:

Patients will be followed for 12 months after the index PCI.

Follow-up will be performed through:

  • Outpatient visits
  • Telephone interviews
  • Review of hospital records
  • Review of repeat angiographic procedures
  • Review of death certificates or official records where available. IX- The primary endpoint will be the occurrence of major adverse cardiovascular events (MACE) during follow-up.

MACE will be defined as a composite of:

  • Cardiovascular death due to new ischemic event.
  • Non-fatal myocardial infarction
  • Unplanned ischemia-driven repeat coronary revascularization
  • Secondary end point : Onset of new ischemic events (UA, worsening of chest pain or ischemic induced heart failure)

Opintotyyppi

Havainnollistava

Ilmoittautuminen (Arvioitu)

440

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei käytössä

Sukupuolet, jotka voivat opiskella

Kaikki

Näytteenottomenetelmä

Todennäköisyysnäyte

Tutkimusväestö

STEMI patients and high risk NSTEMI patients undergoing primary PCI, who have residual untreated coronary disease after the index PCI, will be consecutively enrolled and followed prospectively for clinical outcomes.

Kuvaus

Inclusion Criteria:

  • Age ≥18 years.
  • Patients presenting with STEMI or high risk NSTEMI undergoing primary PCI.
  • Successful PCI of the intended target lesion(s).
  • Evidence of incomplete coronary revascularization after PCI, defined as residual coronary disease resulting in an rSS >0.
  • Availability of adequate pre and post -PCI CBC parameters

Exclusion Criteria:

  • Active infection or systemic inflammatory disease.
  • Known hematological malignancy or major hematological disorder.
  • Recent major surgery or major trauma.
  • Current treatment known to markedly affect leukocyte or platelet counts, such as chronic systemic corticosteroid therapy or cytotoxic therapy.
  • Severe thrombocytopenia or leukopenia which make CBC-derived indices unreliable.
  • Active malignancy.
  • Advanced liver disease with significant hematological abnormalities.
  • End-stage renal disease requiring dialysis

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Havaintomallit: COHORT
  • Aikanäkymät: PROSPECTIVE

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
To determine whether the addition of baseline and post-PCI CBC-derived inflammatory indices (NLR and SII) to rSS improves discrimination for MACE compared with rSS alone by comparing area under curve of rSS combined with NLR and SSI and rSS alone.
Aikaikkuna: from enrollment to the end of follow up in 1 year

comparing Receiver operating characteristic (ROC) curve analysis will be used to assess the ability of rSS alone, and of rSS combined with NLR , to discriminate patients who develop MACE from those who do not. The area under curve ( AUC) of the base model (rSS alone) will be compared with the AUC of the combined model(s) using DeLong's test for correlated ROC curves. NLR is pre-specified as the primary CBC-derived index for this comparison based on its comparatively extensive external validation; SSI will be examined in similar model.

from enrollment to the end of follow up in 1 year

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Arvioitu)

Tiistai 1. joulukuuta 2026

Ensisijainen valmistuminen (Arvioitu)

Keskiviikko 1. joulukuuta 2027

Opintojen valmistuminen (Arvioitu)

Tiistai 1. helmikuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Maanantai 26. lokakuuta 2026

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Ensimmäinen Lähetetty (Todellinen)

Keskiviikko 4. marraskuuta 2026

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Keskiviikko 4. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Ei

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa